Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 1:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Intradialytic Hypertension
Interventions: Carvedilol; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Dallas, Texas

Conditions: Hypertension
Interventions: Feasibility Interview, Team Based Equity Conscious Telemedicine Hypertension Intervention, Usual Care; Other · Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Arterial Hypertension, Atrial Fibrillation
Interventions: Circumferential PV isolation, PV isolation+renal denervation; Procedure
Lead sponsor: Meshalkin Research Institute of Pathology of Circulation; Network
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: verapamil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Prehypertension
Interventions: Labeled prehypertension, Unlabeled prehypertension; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Hypertension
Interventions: sitaxsentan sodium; Drug
Lead sponsor: Encysive Pharmaceuticals; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus, Type 2, Pre-diabetic, Hypertension, Elevated Blood Pressure
Interventions: Sacubitril/Valsartan 200mg (blinded), Valsartan 160mg (blinded); Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Preeclampsia, Hypertensive Disorder of Pregnancy, Toxemia, Pregnancy Complications, Hypertension, Pregnancy-Induced, Hypertension, Obesity, Overweight, Nutrition Disorders, Vascular Diseases, Cardiovascular Diseases, Pre-Eclampsia, Eclampsia, Gestational Hypertension
Interventions: Heart Health Doula Intervention Program, Usual Care; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pulmonary Embolism
Interventions: Macitentan 10mg; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Type 2, Hypertension
Interventions: EXTEND Plus, EXTEND; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 30 Years to 75 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: End Stage Renal Disease, End Stage Renal Disease on Dialysis, Dialysis Hypotension, Dialysis Induced Hypertension
Interventions: Intermittent Non-InvasiveBlood Pressure Monitor; Device
Lead sponsor: The Rogosin Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Parkinson Disease, Supine Hypertension, Neurogenic Orthostatic Hypotension
Interventions: Active CPAP, Sham CPAP, Sleeping in a head-up tilt (HUT) position; Device · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 40 Years to 80 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pulmonary Arterial Hypertension
Interventions: PB1046 Subcutaneous Injection; Drug
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Columbus, Ohio • Pittsburgh, Pennsylvania

Conditions: Hypertension
Interventions: losartan potassium hydrochlorothiazide; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Persistent Fetal Circulation Syndrome, Hypertension, Pulmonary, of Newborn, Persistent, Persistent Pulmonary Hypertension of Newborn
Interventions: Inhaled nitric oxide, Nitrogen Gas, Crossover iNO; Drug
Lead sponsor: University of Florida; Other
Eligibility: 30 Minutes to 48 Hours
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Alzheimer's Disease
Interventions: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine), Aerobic Exercise Training, Usual Care, Stretching Exercise; Drug · Behavioral · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 60 Years to 85 Years
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: Kansas City, Kansas • Baton Rouge, Louisiana • St Louis, Missouri + 1 more

Conditions: Portal Hypertension
Interventions: Transjugular Intrahepatic Portosystemic Shunt; Procedure
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Kidney Injury, Proteinuria, Hypertension
Interventions: Isosorbide Mononitrate, Placebo oral tablet; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertension
Interventions: AVE7688, Losartan-potassium; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 1,940 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Hypertension, Vascular Stiffness
Interventions: Extra Virgin Olive Oil, Control Oil; Dietary Supplement
Lead sponsor: University of Vermont Medical Center; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Hypertension in Pregnancy, Preeclampsia Severe, Gestational Hypertension, Postpartum Preeclampsia, Postpartum
Interventions: NIFEdipine ER, Enalapril; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Depression, Diabetes, Hypertension, Hypercholesterolemia
Interventions: Holistic health; Behavioral
Lead sponsor: Duke Clergy Health Initiative; Other
Eligibility: 18 Years and older
Enrollment: 1,114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Sarcoidosis-associated Pulmonary Hypertension
Interventions: Selexipag, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Indianapolis, Indiana • New Orleans, Louisiana • New York, New York + 5 more

Conditions: Elevated Intracranial Pressure
Interventions: hypertonic saline, Mannitol; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Mechanisms and Treatment of Intradialytic Hypertension

Team Based Equity Conscious Telemedicine Approach to Hypertension

Combined Treatment of Arterial Hypertension and Atrial Fibrillation

Bioequivalence Study Of Verapamil

Prehypertension Labeling

Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension

Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition

Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial

Macitentan to Prevent PRVO

Expanding Technology-Enabled Nurse Delivered Chronic Disease Care

Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis)

CPAP for the Treatment of Supine Hypertension

A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH

Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg /25 mg Tablet Under Fed Conditions

Early iNO for Oxidative Stress, Vascular Tone and Inflammation in Babies With Hypoxic Respiratory Failure

Risk Reduction for Alzheimer's Disease

Ultrasound Elastography Assessment of Spleen and Liver Stiffness Before and After Transjugular Intrahepatic Portosystemic Shunt (TIPS) Procedure

Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury

AVE7688 in Patients With Mild to Moderate Blood Pressure

Cardiovascular Effects of EVOO in Healthy Reproductive-aged Women

Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period

Study of a Holistic Health Program for United Methodist Clergy

A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag

Double Blind Study of Hypertonic Saline vs Mannitol in the Management of Increased Intracranial Pressure (ICP).